Literature DB >> 20056923

Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: the evaluation of vascular care in Alzheimer's disease (EVA) study.

Edo Richard, Alida A Gouw, Philip Scheltens, Willem A van Gool.   

Abstract

BACKGROUND AND
PURPOSE: White matter lesions (WMLs) and cerebral infarcts are common findings in Alzheimer disease and may contribute to dementia severity. WMLs and lacunar infarcts may provide a potential target for intervention strategies. This study assessed whether multicomponent vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of WMLs and prevents occurrence of new infarcts.
METHODS: A randomized controlled clinical trial, including 123 subjects, compared vascular care with standard care in patients with Alzheimer disease with cerebrovascular lesions on MRI. Progression of WMLs, lacunes, medial temporal lobe atrophy, and global cortical atrophy were semiquantitatively scored after 2-year follow-up.
RESULTS: Sixty-five subjects (36 vascular care, 29 standard care) had a baseline and a follow-up MRI and in 58 subjects, a follow-up scan could not be obtained due to advanced dementia or death. Subjects in the vascular care group had less progression of WMLs as measured with the WML change score (1.4 versus 2.3, P=0.03). There was no difference in the number of new lacunes or change in global cortical atrophy or medial temporal lobe atrophy between the 2 groups.
CONCLUSIONS: Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of WMLs. Treatment aimed at vascular risk factors in patients with early Alzheimer disease may be beneficial, possibly in an even earlier stage of the disease.

Entities:  

Mesh:

Year:  2010        PMID: 20056923     DOI: 10.1161/STROKEAHA.109.571281

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  28 in total

1.  An MRI-based semiquantitative index for the evaluation of brain atrophy and lesions in Alzheimer's disease, mild cognitive impairment and normal aging.

Authors:  Wei Chen; Xiaowei Song; Yunting Zhang; Sultan Darvesh; Ningnannan Zhang; Ryan C N D'Arcy; Sandra Black; Kenneth Rockwood
Journal:  Dement Geriatr Cogn Disord       Date:  2010-08-21       Impact factor: 2.959

2.  Cognition and Hemodynamics.

Authors:  Vera Novak
Journal:  Curr Cardiovasc Risk Rep       Date:  2012-10

Review 3.  White matter hyperintensities, cognitive impairment and dementia: an update.

Authors:  Niels D Prins; Philip Scheltens
Journal:  Nat Rev Neurol       Date:  2015-02-17       Impact factor: 42.937

4.  The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment.

Authors:  Giuseppe Tosto; Molly E Zimmerman; Jamie L Hamilton; Owen T Carmichael; Adam M Brickman
Journal:  Alzheimers Dement       Date:  2015-06-13       Impact factor: 21.566

Review 5.  Imaging small vessel-associated white matter changes in aging.

Authors:  D H Salat
Journal:  Neuroscience       Date:  2013-12-06       Impact factor: 3.590

6.  Treatment of Vascular Cognitive Impairment.

Authors:  Aaron Ritter; Jagan A Pillai
Journal:  Curr Treat Options Neurol       Date:  2015-08       Impact factor: 3.598

Review 7.  Cerebral white matter hyperintensities in the prediction of cognitive decline and incident dementia.

Authors:  Marion Mortamais; Sylvaine Artero; Karen Ritchie
Journal:  Int Rev Psychiatry       Date:  2013-12

8.  Two distinct classes of degenerative change are independently linked to clinical progression in mild cognitive impairment.

Authors:  Jean-Philippe Coutu; Emily R Lindemer; Ender Konukoglu; David H Salat
Journal:  Neurobiol Aging       Date:  2017-02-16       Impact factor: 4.673

Review 9.  The pathobiology of vascular dementia.

Authors:  Costantino Iadecola
Journal:  Neuron       Date:  2013-11-20       Impact factor: 17.173

Review 10.  The pericyte: a forgotten cell type with important implications for Alzheimer's disease?

Authors:  Ethan A Winkler; Abhay P Sagare; Berislav V Zlokovic
Journal:  Brain Pathol       Date:  2014-07       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.